Tagungsprogramm
(Scientific Program)

XXXII. Jahrestagung der Kind-Philipp-Stiftung
für Leukämieforschung
in Wilsede
vom 5. – 7. Juni 2019

Ausrichter (organized by):
Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Halle; Institut für Pharmazeutische Biologie, Goethe Universität Frankfurt am Main; Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover; Princess Maxima Center for Pediatric Oncology, Utrecht
Supported by:

- Stifterverband für die deutsche Wissenschaft, DSZ Deutsches Stiftungszentrum, Kind-Philipp-Stiftung
- Verein für krebserkrankte Kinder Hannover e.V.
- Roche Pharma AG, Grenzach-Wyhlen
- Förderverein für krebskranke Kinder e.V. Freiburg
- SERVIER Deutschland GmbH, München
- Eurocept International B.V., Ankeveen
- Hilfe für krebskranke Kinder Frankfurt e.V.
- Abteilung für Kinder- und Jugendmedizin des Universitätsklinikums Ulm
- Fördergemeinschaft Kinderkrebs-Zentrum Hamburg e.V.
# PROGRAM AT A GLANCE

<table>
<thead>
<tr>
<th>Wednesday, June 5</th>
<th>Thursday, June 6</th>
<th>Friday, June 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-17:30</td>
<td>9:00-10:45</td>
<td>9:00-10:30</td>
</tr>
<tr>
<td>Welcome and registration</td>
<td>Molecular mechanisms of disease I</td>
<td>Immunotherapy</td>
</tr>
<tr>
<td>17:30-18:30</td>
<td>11:00-12:45</td>
<td>10:45-12:30</td>
</tr>
<tr>
<td>Invited Lecture: T. Mercher</td>
<td>Drugs I</td>
<td>Molecular mechanisms of disease III</td>
</tr>
<tr>
<td>18:30-19:45</td>
<td>17:45-18:45</td>
<td>12:30-13:45</td>
</tr>
<tr>
<td>Omics Studies</td>
<td>Diagnostics and Biomarkers</td>
<td>Lunch at Heidemuseum</td>
</tr>
<tr>
<td>19:45</td>
<td>14:15-15:45</td>
<td>13:45-15:00</td>
</tr>
<tr>
<td>Dinner</td>
<td></td>
<td>Molecular mechanisms of disease IV</td>
</tr>
</tbody>
</table>

## WEDNESDAY, June 5, 2019

16:00 - 17:30 h  
Welcome and registration

17:30 – 17:45 h  
Opening of the meeting – Rolf Marschalek

17:45 – 18:30 h  
(1) Opening Lecture  
*Chair: Jan-Henning Klusmann*  
*Prof. Dr. Thomas Mercher*  
Ontogeny-dependent susceptibility to fusion oncogenes controls pediatric myeloid leukemia  
Institut Gustave Roussy; Villejuif

18:30 – 19:45 h  
(2) Omics studies  
*Chair: Thomas Sterndorf*  
2.a Mutational and transcriptomic landscapes in hematopoietic cells of Fanconi anemia patients.  
*Mittapalli, VR; Freiburg*  
2.b Mapping the single cell transcriptome reveals the cellular composition of ATRT subgroups  
*Buellesbach, A; Heidelberg*  
2.c Giant cell glioblastoma does not represent a distinct entity but stratifies into different genetically defined entities  
*Wiedey, A; Bonn*  
2.d WNT Medulloblastoma: More than just β-Catenin Mutations – Rare Genetic Features in the Focus  
*Goschzik, T; Bonn*  
2.e Epigenetics profiling for minimal residual disease in paediatric acute myeloid leukaemia  
*Al Ameri, M; London*  

19:45  
Dinner
THURSDAY, June 6, 2019

09:00 - 10:45 h  (3) Molecular mechanisms of disease I
Chair: Owen Williams
3. a Splicing factors of the SF3b complex PHF5A and SF3B1 regulate the DNA damage response in ALL
Moorthy, S; Newcastle upon Tyne
3. b Inactivation of Nsd1 impairs terminal erythroid maturation and induces erythroleukemia
Tauchmann, S; Basel
3. c TRIM28 haploinsufficiency predisposes to Wilms tumor
Metzler, M; Erlangen
3. d CRISPR-mediated genome editing of t(4;11) in human prenatal and perinatal hematopoietic stem/progenitor cells
Torres-Ruiz, R; Barcelona
3. e Therapeutic application of the tumour suppressive miR-193b in acute myeloid leukaemia
Issa, H; Halle
3. f Genome-wide CRISPR screen in patient derived cells reveals the mechanism of ALL chemoresistance
Szoltysek, K; Newcastle upon Tyne
3. g CRISPRi screen to identify functional long noncoding RNAs in pediatric acute myeloid leukemia
Ng, M; Halle

10:45 - 11:00 h  Coffee break

11:00 - 12:45 h  (4) Drugs I
Chair: Torsten Pietsch
4. a Tumour Necrosis Factor receptor (TNFR)-signalling dependent killing in T-cell acute lymphoblastic leukaemia (T-ALL)
Krippner-Heidenreich, A; Utrecht
4. b iPSC Model of Stepwise Leukemia Development in Congenital Neutropenia Reveals BAALC as a Key Mediator of Leukemogenesis
Dannenmann, B; Tübingen
4. c Targeting c-MYB in Acute Leukaemia through Drug Repositioning
Clesham KJ; London
4. d Functional analysis of class I HDAC inhibition in group 3 medulloblastoma to identify synergistic drug combinations
Vollmer, J; Heidelberg
4. e Screening assay to identify potential Taspase1 inhibitors
Luciano, V; Frankfurt
4. f Analyzing the therapeutic efficacy of navitoclax and MCL-1 inhibitors in juvenile myelomonocytic leukemia
Wu, Y; Freiburg
4. g Establishment of new therapeutic options for the treatment of Myeloid Leukemia in Down syndrome (ML-DS)
Samulowski, D; Halle

12:45 - 14:15 h  Lunch (Wilsede, Heidemuseum)
14:15 – 15:45 h

(5) Diagnostics and Biomarkers

Chair: Roland Kappler

5.a Masked hypodiploidy against uniparental disomies in hyperdiploid ALL: Observations from the diagnostics perspective
Schieck, M; Hannover

5.b Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukemia (CML)
Krumbholz, M; Erlangen

5.c Stratification and prognosis of IGH-DUX4 positive acute lymphoblastic leukemia in children
Müller, J; Kiel

5.d Multiplex droplet digital PCR-based targeted enrichment NGS for identification of tumor markers in Ewing sarcoma (EwS)
Eiblwieser, J; Erlangen

5.e Machine learning algorithms for the automated classification of pediatric anemia
Zierk, J; Erlangen

5.f Identification of the genetic mechanisms linked to the occurrence of H3.3K27M mutation in pediatric diffuse intrinsic pontine gliomas
Kubiak, K; Göttingen

15:45 – 16:15 h

Coffee Break

16:15 – 17:45 h

(6) Molecular mechanisms of disease II

Chair: Deepali Pal

6.a Deciphering the interactive network of the DLK1-DIO3 locus in hematopoiesis and pediatric acute megakaryoblastic leukemia
Verboon LJ; Halle

6.b Identification of GATA1s interaction partners in Down syndrome-associated myeloid leukemia
Bräuer-Hartmann, D; Halle

6.c Isolation and characterization of tumor-derived exosomes from a patient-derived xenograft mouse model of acute leukemia
Bartholomé, R; München

6.d Interrogating the role of chromatin regulator BRD4 in the DNA damage response in medulloblastoma
Vu-Han, T-L; Hamburg

6.e Analyzing the effects of oncogenic SHP2 on apoptosis signaling during malignant transformation
Koleci, N; Freiburg

6.f Chromosome structure and mitotic defects are major pathogenic mechanisms in hyperdiploid childhood B-ALL.
Molina, O; Barcelona

18:15 - 19:00 h

(7) Invited Lecture:
Senior-Prof. em. Dr. Meinolf Suttorp Chair: Karl Welte
Do you know a chimera?
Pediatric Hematology and Oncology
Medical Faculty, Technical University Dresden; Dresden

19:00 h

Starting later

Barbecue

Evening with the famous Mac-Guitar
FRIDAY, June 7, 2019

09:00 - 10:30 h  
(8) Immunotherapy  
Chair: Olaf Heidenreich

8.a Development of a novel central nervous system (CNS)-targeted CD19-antibody (AB) in acute lymphoblastic leukemia (ALL)  
Winterberg, D; Kiel

8.b CD19 and CD22-directed bispecific CAR for B-cell acute lymphoblastic leukemia  
Zanetti, SR; Barcelona

8.c Low regulatory T-cells are associated with improved survival of neuroblastoma patients treated with anti-GD2 antibodies  
Troschke-Meurer, S; Greifswald

8.d CRISPR/Cas9 Gene-modification Platform of ELANE Mutations in iPSCs and HSPCs of Severe Congenital Neutropenia Patients  
Nasri, M; Tübingen

8.e Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies  
Heymann, J; Kiel

8.f Blockade of suppressive myeloid cells is effective against neuroblastoma von Lojewski, L; Tübingen

10:30 – 10:45 h  
Coffee break

10:45 - 12:30 h  
(9) Molecular mechanisms of disease III  
Chair: Jasper de Boer

9.a Too little is too much: Leukemogenesis in the Gata2 syndrome  
Weiss, JM; Freiburg

9.b Using acute promyelocytic leukemia to study the H3.3 histone chaperone system and its role in pediatric malignancies  
Cui, W; Hamburg

9.c Functional characterization of RUNX1 variants in the context of FPDMM  
Decker, M; Hannover

9.d FOS and FOSB are linked with CNS-infiltration and inferior prognosis in childhood T-cell acute lymphoblastic leukemia  
Spory, L; Kiel

9.e Deciphering role of lncRNAs in pediatric AML  
Bhayadia, R; Halle

9.f Genomic characterisation of lineage switched MLL-rearranged leukemias  
Tirtakusuma, R; Newcastle upon Tyne

9.g Downstream effect of CSF3R and RUNX1 mutations that underlie leukemic transformations in congenital neutropenia (CN)  
Ritter, MU; Tübingen

12:30 - 13:45 h  
Lunch (Wilsede, Heidemuseum)
13:45 - 15:00 h  
(10) Molecular mechanisms of disease IV  
Chair: Markus Metzler  
10.a Identification of a new splice variant of the human transcription factor ONECUT2  
Lein, P; Halle  
10.b NAMPT-mediated LMO2 deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis  
Morishima, T; Tübingen  
10.c GADD45b plays an essential role in the G-CSF triggered granulocytic differentiation of human hematopoietic cells  
Mir, P; Tübingen  
10.d Tripartite motif-containing 71 (TRIM71) is a major factor of oncogenic activity in human hepatoblastoma  
Jiang, T; München  
10.e Cooperativity between miR-125b and Gata1s in the pathogenesis of Down syndrome-associated myeloid leukemia  
Alejo-Valle, O; Halle  

15:00 - 15:15 h  
Coffee break  

15:15 - 16:45 h  
(11) Drugs II  
Chair: Julia Skokowa  
11.a Investigating HDACi and dnTaspase1 for the treatment of (4;11) leukemic cells  
Wilhelm, A; Frankfurt  
11.b Dasatinib and dexamethasone offer a novel therapeutic strategy for T-cell acute lymphoblastic leukaemia  
Yuzhe, S; Newcastle upon Tyne  
11.c Drug repositioning in infant leukaemia  
Looi-Somoye, R; London  
11.d Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias  
Hinze, L; Hannover  
11.e A human BM-iPSC-derived oncogenic niche identifies CDH2 as therapeutic niche target in leukemia  
Pal, D; Newcastle upon Tyne  
11.f Inhibition of the polycomb repressive complex 1 (PRC1) as a therapeutic option in childhood liver tumors  
Bentrop, M; München  

16:45 - 17:00 h  
Wilsede Award and subsequent closure of the meeting – Martin Stanulla  

16:50 - 17:15 h  
Farewell at the Emhoff  

17:15 h  
Departure of the coaches to Undeloh  

18:00 h  
Bus transfer to Hamburg Dammtor railway station